These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 35149964)
21. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617 [TBL] [Abstract][Full Text] [Related]
22. Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes. Zarranz-Ventura J; Parrado-Carrillo A; Nguyen V; Sararols L; Garay-Aramburu G; Puzo M; Arruabarrena C; Figueras-Roca M; Gillies MC; Casaroli-Marano RP; Clin Exp Ophthalmol; 2022 Apr; 50(3):312-324. PubMed ID: 35106882 [TBL] [Abstract][Full Text] [Related]
23. SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States. Khanani AM; Skelly A; Bezlyak V; Griner R; Torres LR; Sagkriotis A Ophthalmol Retina; 2020 Feb; 4(2):122-133. PubMed ID: 31812631 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration. Razavi S; Kodjikian L; Giocanti-Aurégan A; Dufour I; Souied E BMC Ophthalmol; 2021 Feb; 21(1):90. PubMed ID: 33596867 [TBL] [Abstract][Full Text] [Related]
26. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom. Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918 [TBL] [Abstract][Full Text] [Related]
27. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. Lotery A; Griner R; Ferreira A; Milnes F; Dugel P Eye (Lond); 2017 Dec; 31(12):1697-1706. PubMed ID: 28731052 [TBL] [Abstract][Full Text] [Related]
28. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration. Park DH; Sun HJ; Lee SJ Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933 [TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes of switching to aflibercept for treatment-resistant neovascular age-related macular degeneration. Spooner K; Hong T; Nair R; Chow NCC; Broadhead GK; Wijeyakumar W; Chang AA Acta Ophthalmol; 2019 Aug; 97(5):e706-e712. PubMed ID: 30740921 [TBL] [Abstract][Full Text] [Related]
30. Exploration of real-world outcomes and treatment patterns in patients treated with anti-vascular endothelial growth factors for neovascular age-related macular degeneration in Sweden. Schroeder M; Westborg I; Fluur C; Olsen R; Lövestam-Adrian M Acta Ophthalmol; 2022 Jun; 100(4):e928-e935. PubMed ID: 34543528 [TBL] [Abstract][Full Text] [Related]
31. Outcomes of Eyes Lost to Follow-up with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Anti-Vascular Endothelial Growth Factor. Soares RR; Mellen P; Garrigan H; Obeid A; Wibbelsman TD; Borkar D; Ho AC; Hsu J Ophthalmol Retina; 2020 Feb; 4(2):134-140. PubMed ID: 31540854 [TBL] [Abstract][Full Text] [Related]
32. Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis. Tsai CY; Wu CL; Cheng CK; Shen YD; Wu WC; Wu PC; Tsai A; Chen JT BMC Ophthalmol; 2023 Jan; 23(1):39. PubMed ID: 36707779 [TBL] [Abstract][Full Text] [Related]
33. Four-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Results from real-life setting. Lukic M; Eleftheriadou M; Hamilton RD; Rajendram R; Bucan K; Patel PJ Eur J Ophthalmol; 2021 Jul; 31(4):1940-1944. PubMed ID: 32586117 [TBL] [Abstract][Full Text] [Related]
39. Comparison of agents using higher dose anti-VEGF therapy for treatment-resistant neovascular age-related macular degeneration. Broadhead GK; Keenan TDL; Chew EY; Wiley HE; Cukras CA Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2239-2247. PubMed ID: 35092447 [TBL] [Abstract][Full Text] [Related]
40. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry. Rao P; Lum F; Wood K; Salman C; Burugapalli B; Hall R; Singh S; Parke DW; Williams GA Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]